These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Management of overactive bladder syndrome. Srikrishna S; Robinson D; Cardozo L; Vella M Postgrad Med J; 2007 Jul; 83(981):481-6. PubMed ID: 17621619 [TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. Homma Y; Paick JS; Lee JG; Kawabe K; BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458 [TBL] [Abstract][Full Text] [Related]
24. Overactive bladder in children. Franco I Nat Rev Urol; 2016 Sep; 13(9):520-32. PubMed ID: 27530266 [TBL] [Abstract][Full Text] [Related]
25. Augmentation enterocystoplasty in overactive bladder: is there still a role? Reyblat P; Ginsberg DA Curr Urol Rep; 2010 Nov; 11(6):432-9. PubMed ID: 20734172 [TBL] [Abstract][Full Text] [Related]
26. The pharmacotherapy of overactive bladder. Athanasopoulos A Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348 [TBL] [Abstract][Full Text] [Related]
27. In women with urinary incontinence how necessary is cystometry? Saleem A J Pak Med Assoc; 2010 May; 60(5):356-9. PubMed ID: 20527606 [TBL] [Abstract][Full Text] [Related]
28. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. Malone-Lee J; Henshaw DJ; Cummings K BJU Int; 2003 Sep; 92(4):415-7. PubMed ID: 12930431 [TBL] [Abstract][Full Text] [Related]
29. [Overactive bladder--treatment with antimuscarinic agents]. Höfner K Urologe A; 2003 Jun; 42(6):793-800. PubMed ID: 12851770 [TBL] [Abstract][Full Text] [Related]
30. Urinary incontinence in men: current and developing therapy options. Burden H; Abrams P Expert Opin Pharmacother; 2016; 17(5):715-26. PubMed ID: 26800277 [TBL] [Abstract][Full Text] [Related]
32. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. Liu HT; Chen CY; Kuo HC J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884 [TBL] [Abstract][Full Text] [Related]
33. [The medical treatment of overactive bladder]. Beneton C; De Parisot O Neurochirurgie; 2003 May; 49(2-3 Pt 2):369-76. PubMed ID: 12746713 [TBL] [Abstract][Full Text] [Related]
37. Update on the pharmacologic management of overactive bladder: the present and the future. Ellsworth P; Kirshenbaum E Urol Nurs; 2010; 30(1):29-38, 53. PubMed ID: 20359143 [TBL] [Abstract][Full Text] [Related]
38. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028 [TBL] [Abstract][Full Text] [Related]